{
  "docId": "019de073-ed1e-723c-a28e-3c378280574e",
  "docSlug": "3439c61eec2c1805f58a361a1d0fbc84",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 36,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 15,
  "notes": "Includes clinical trial data visualization and product summary table.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-ed1e-723c-a28e-3c378280574e/12",
  "deckHref": "/decks/019de073-ed1e-723c-a28e-3c378280574e",
  "deckJsonHref": "/decks/019de073-ed1e-723c-a28e-3c378280574e.json",
  "deckAnchorHref": "/decks/019de073-ed1e-723c-a28e-3c378280574e#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.58,
        "x": 0.37,
        "y": 0.32
      },
      "kind": "chart",
      "text": "COMP360 Phase 2b trial results showing MADRS score reduction over 12 weeks for 25mg, 10mg, and 1mg doses.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01f28fea-1047-48e3-b296-baa60f277567",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.37,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Source: Schedule 13D filed with the SEC as of November 29th, 2021. Note: MADRS = Montgomery-Åsberg Depression Rating Scale.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74fda0f4-cf4f-4c46-a1a6-1e9240dc4fd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.67,
        "w": 0.32,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "table",
      "text": "Ownership: 22.5%, Product: Oral Psilocybin, Pharmacology: 5-HT2A-R agonist, Features: Rapid onset, Indications: TRD/Anorexia, Status: Phase 3, IP: Proprietary formulation, Highlight: Efficacy in Phase 2b",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d452a97e-6d73-4eaf-bfd4-79c26d8ef7a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.58,
        "x": 0.37,
        "y": 0.08
      },
      "kind": "title",
      "text": "COMP360 Phase 2b trial showed a rapid, sustained reduction in depressive symptoms",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43677398-b780-4151-b883-e283169d9428",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.13,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f3c1550-b14d-458f-8445-ccb80eb8c442",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}